(0.21%) 5 110.87 points
(0.34%) 38 370 points
(0.27%) 15 970 points
(-1.36%) $82.71
(5.77%) $2.03
(0.20%) $2 351.90
(0.01%) $27.54
(3.95%) $958.55
(-0.24%) $0.932
(-0.36%) $10.99
(-0.56%) $0.796
(1.65%) $93.39
1.41% ¥ 1 512.50
Live Chart Being Loaded With Signals
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial...
Stats | |
---|---|
Dzisiejszy wolumen | 2.72M |
Średni wolumen | 1.51M |
Kapitalizacja rynkowa | 549.90B |
EPS | ¥0 ( 2024-02-07 ) |
Następna data zysków | ( ¥13.64 ) 2024-05-08 |
Last Dividend | ¥16.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 20.28 |
ATR14 | ¥0.772 (0.05%) |
Wolumen Korelacja
Santen Pharmaceutical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Santen Pharmaceutical Korelacja - Waluta/Towar
Santen Pharmaceutical Finanse
Annual | 2022 |
Przychody: | ¥279.04B |
Zysk brutto: | ¥166.09B (59.52 %) |
EPS: | ¥-38.58 |
FY | 2022 |
Przychody: | ¥279.04B |
Zysk brutto: | ¥166.09B (59.52 %) |
EPS: | ¥-38.58 |
FY | 2022 |
Przychody: | ¥266.26B |
Zysk brutto: | ¥156.59B (58.81 %) |
EPS: | ¥68.07 |
FY | 2021 |
Przychody: | ¥249.61B |
Zysk brutto: | ¥151.38B (60.65 %) |
EPS: | ¥17.09 |
Financial Reports:
No articles found.
Santen Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥16.00 (N/A) |
¥0 (N/A) |
¥16.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥2.00 | 2001-03-27 |
Last Dividend | ¥16.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥423.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.84 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.72 | |
Div. Directional Score | 7.93 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8365.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7745.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6927.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6289.T | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
5011.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4212.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3420.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2502.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9436.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8089.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0918 | 1.500 | 8.16 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0648 | 1.200 | 7.84 | 9.41 | [0 - 0.3] |
returnOnEquityTTM | 0.0924 | 1.500 | -0.0848 | -0.127 | [0.1 - 1] |
payoutRatioTTM | 0.429 | -1.000 | 5.71 | -5.71 | [0 - 1] |
currentRatioTTM | 2.46 | 0.800 | 2.72 | 2.17 | [1 - 3] |
quickRatioTTM | 1.841 | 0.800 | 3.88 | 3.10 | [0.8 - 2.5] |
cashRatioTTM | 0.897 | 1.500 | 6.13 | 9.19 | [0.2 - 2] |
debtRatioTTM | 0.0786 | -1.500 | 8.69 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 20.13 | 1.000 | 3.66 | 3.66 | [3 - 30] |
operatingCashFlowPerShareTTM | 192.60 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 162.21 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.113 | -1.500 | 9.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.606 | 1.000 | 3.24 | 3.24 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.143 | 1.000 | 9.14 | 9.14 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.03 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.706 | 0.800 | 8.63 | 6.90 | [0.5 - 2] |
Total Score | 11.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 19.29 | 1.000 | 8.15 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0924 | 2.50 | -0.0545 | -0.127 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 162.21 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.18 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 192.60 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.429 | 1.500 | 5.71 | -5.71 | [0 - 1] |
pegRatioTTM | -0.123 | 1.500 | -4.15 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.225 | 1.000 | 6.86 | 0 | [0.1 - 0.5] |
Total Score | 4.72 |
Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej